

Citations

1. Mohr D, Bowry VW, Stocker R. Dietary supplementation with coenzyme Q10 results in increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance of human low-density lipoprotein to the initiation of lipid peroxidation. *Biochim Biophys Acta* 1992;1126:247-254.
2. Crane FL. Biochemical functions of coenzyme Q10. *J Am Coll Nutr* 2001;20:591-598.
3. Zhang Y, Aberg F, Appelkvist EL et al. Uptake of dietary coenzyme Q supplement is limited in rats. *J Nutr* 1995;125:446-453.
4. Lonnrot K, Holm P, Lagerstedt A et al. The effects of lifelong ubiquinone Q10 supplementation on the Q9 and Q10 tissue concentrations and life span of male rats and mice. *Biochem Mol Biol Int* 1998;44:727-737.
5. Matthews RT, Yang L, Browne S et al. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. *Proc Natl Acad Sci U S A* 1998;95:8892-8897.
6. Svensson M, Malm C, Tonkonogi M et al. Effect of Q10 supplementation on tissue Q10 levels and adenine nucleotide catabolism during high-intensity exercise. *Int J Sport Nutr* 1999;9:166-180.
7. Rosenfeldt FL, Pepe S, Linnane A et al. The effects of ageing on the response to cardiac surgery: protective strategies for the ageing myocardium. *Biogerontology* 2002;3:37-40.
8. Kalen A, Appelkvist EL, Dallner G. Age-related changes in the lipid compositions of rat and human tissues. *Lipids* 1989;24:579-584.
9. Soderberg M, Edlund C, Kristensson K, Dallner G. Lipid compositions of different regions of the human brain during aging. *J Neurochem* 1990;54:415-423.
10. Miles MV, Morrison JA, Horn PS, et al. LPL and NQO1 genotypes are associated with decreased coenzyme Q10 redox ratio. International Congress of Clinical Chemistry and American Association for Clinical Chemistry Annual Meeting; 2005.
11. Weber C, Bysted A, Hllmer G. The coenzyme Q10 content of the average Danish diet. *Int J Vitam Nutr Res* 1997;67:123-129.
12. Overvad K, Diamant B, Holm L et al. Coenzyme Q10 in health and disease. *Eur J Clin Nutr* 1999;53:764-770.
13. Terao K, Nakata D, Fukumi H et al. Enhancement of oral bioavailability of coenzyme Q10 by complexation with alpha-cyclodextrin in healthy adults. *Nutr Res* 2006;26:503-508.
14. Ueda T, Ono T, Moro M et al. Method of stabilizing reduced coenzyme Q10. US patent application: US 2005/008630 A1; 2005.
15. Weis M, Mortensen SA, Rassing MR et al. Bioavailability of four oral coenzyme Q10 formulations in healthy volunteers. *Mol Aspects Med* 1994;15 Suppl:s273-s280.
16. Kaikkonen J, Nyyssonen K, Porkkala-Sarataho E et al. Effect of oral coenzyme Q10 supplementation on the oxidation resistance of human VLDL+LDL fraction: absorption and antioxidative properties of oil and granule-based preparations. *Free Radic Biol Med* 1997;22:1195-1202.
17. Chopra RK, Goldman R, Sinatra ST, Bhagavan HN. Relative bioavailability of coenzyme Q10 formulations in human subjects. *Int J Vitam Nutr Res* 1998;68:109-113.
18. Langsjoen PH. Personal communication with MB Stargrove. May 2004.
19. Ikematsu H, Nakamura K, Harashima SI et al. Safety assessment of coenzyme Q10 (Kaneka Q10) in healthy subjects: a double-blind, randomized, placebo-controlled trial. *Regul Toxicol Pharmacol* 2006;44:212-218.
20. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. *Neurology* 2001;57:397-404.
21. Shults CW, Oakes D, Kieburtz K et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. *Arch Neurol* 2002;59:1541-1550.
22. Damian MS, Ellenberg D, Gildemeister R et al. Coenzyme Q10 combined with mild hypothermia after cardiac arrest: a preliminary study. *Circulation* 2004;110:3011-3016.
23. Studer M, Briel M, Leimenstoll B et al. Effect of different antilipidemic agents and diets on mortality: a systematic review. *Arch Intern Med* 2005;165:725-730.
24. Silver MA, Langsjoen PH, Szabo S et al. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q(10) to reverse that dysfunction. *Am J Cardiol* 2004;94:1306-1310.
25. Go AS, Lee WY, Yang J et al. Statin therapy and risks for death and hospitalization in chronic heart failure. *JAMA* 2006;296:2105-2111.
26. Getz L, Sigurdsson JA, Hetlevik I et al. Estimating the high risk group for cardiovascular disease in the Norwegian HUNT 2 population according to the 2003 European guidelines: modelling study. *BMJ* 2005;331:551.
27. Ravnskov U, Rosch PJ, Sutter MC, Houston MC. Should we lower cholesterol as much as possible? *BMJ* 2006;332:1330-1332.
28. May HT, Muhlestein JB, Carlquist JF et al. Relation of serum total cholesterol, C-reactive protein levels, and statin therapy to survival in heart failure. *Am J Cardiol* 2006;98:653-658.
29. Tsivgoulis G, Spengos K, Karandreas N et al. Presymptomatic neuromuscular disorders disclosed following statin treatment. *Arch Intern Med* 2006;166:1519-1524.

Citations and Reference Literature: Coenzyme Q10

30. Rauramaa R, Halonen P, Vaisanen SB et al. Effects of aerobic physical exercise on inflammation and atherosclerosis in men: the DNASCO Study: a six-year randomized, controlled trial. *Ann Intern Med* 2004;140:1007-1014.
31. Cowell SJ, Newby DE, Prescott RJ et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. *N Engl J Med* 2005;352:2389-2397.
32. Pedersen TR, Faergeman O, Kastelein JJP et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study, a randomized controlled trial. *JAMA* 2005;294:2437-2445.
33. Chasman DI, Posada D, Subrahmanyam L et al. Pharmacogenetic study of statin therapy and cholesterol reduction. *JAMA* 2004;291:2821-2927.
34. Wilke RA, Moore JH, Burmester JK. Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. *Pharmacogenet Genomics* 2005;15:415-421.
35. Krauss RM, Yang H, Rieder MJ et al. Haplotypes in the HMGCoA reductase gene influence plasma LDL level and LDL response to statin in African Americans and Caucasians. Abstract 725. American Heart Association Scientific Sessions 2005. Dallas, Texas; 2005.
36. Sirtori CR, Calabresi L, Ferrara S et al. L-carnitine reduces plasma lipoprotein(a) levels in patients with hyper Lp(a). *Nutr Metab Cardiovasc Dis* 2000;10:247-251.
37. Montori VM, Farmer A, Wollan PC, Dinneen SF. Fish oil supplementation in type 2 diabetes: a quantitative systematic review. *Diabetes Care* 2000;23:1407-1415.
38. Durrington PN, Bhatnagar D, Mackness MI et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. *Heart* 2001;85:544-548.
39. Chan DC, Watts GF, Barrett PH et al. Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity. *Clin Chem* 2002;48:877-883.
40. Chan DC, Watts GF, Barrett PH et al. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. *Diabetes* 2002;51:2377-2386.
41. Brescia F, Balestra E, Iasella MG, Damato AB. Effects of combined treatment with simvastatin and L-carnitine on triglyceride levels in diabetic patients with hyperlipidaemia. *Clin Drug Invest* 2002;22:23-28.
42. Derosa G, Cicero AF, Gaddi A et al. The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. *Clin Ther* 2003;25:1429-1439.
43. Solfrizzi V, Capurso C, Colacicco AM et al. Efficacy and tolerability of combined treatment with L-carnitine and simvastatin in lowering lipoprotein(a) serum levels in patients with type 2 diabetes mellitus. *Atherosclerosis* 2006;188:455-461.
44. Levy HB, Kohlhaas HK. Considerations for supplementing with coenzyme Q10 during statin therapy. *Ann Pharmacother* 2006;40:290-294.
45. Kerns W 2nd, Kline J, Ford MD. Beta-blocker and calcium channel blocker toxicity. *Emerg Med Clin North Am* 1994;12:365-390.
46. Folkers K, Vadhanavikit S, Mortensen SA. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10. *Proc Natl Acad Sci U S A* 1985;82:901-904.
47. Kishi H, Kishi T, Folkers K. Bioenergetics in clinical medicine. III. Inhibition of coenzyme Q10-enzymes by clinically used anti-hypertensive drugs. *Res Commun Chem Pathol Pharmacol* 1975;12:533-540.
48. Kishi T, Watanabe T, Folkers K. Bioenergetics in clinical medicine. XV. Inhibition of coenzyme Q10-enzymes by clinically used adrenergic blockers of beta-receptors. *Res Commun Chem Pathol Pharmacol* 1977;17:157-164.
49. Kishi T, Makino K, Okamoto T et al. Inhibition of myocardial respiration by psychotherapeutic drugs and prevention by coenzyme Q10. In: Yamamura Y, Folkers K, Ito Y, eds. *Biochemical and Clinical Aspects of Coenzyme Q*. 2 vol. Amsterdam: Elsevier/North Holland Biomedical Press; 1980:139-157.
50. Hamada M, Kazatain Y, Ochi T et al. Correlation between serum CoQ10 level and myocardial contractility in hypertensive patients. In: Folkers K, Yamamura Y, ed. *Biomedical and Clinical Aspects of Coenzyme Q*. 4 vol. Amsterdam: Elsevier; 1984:263-270.
51. Takahashi N, Iwasaka T, Sugiura T et al. Effect of coenzyme Q10 on hemodynamic response to ocular timolol. *J Cardiovasc Pharmacol* 1989;14:462-468.
52. Lenaz G. *Coenzyme Q*. New York: Wiley & Sons; 1985.
53. Iwamoto Y, Hansen IL, Porter TH, Folkers K. Inhibition of coenzyme Q10-enzymes, succinoxidase and NADH-oxidase, by Adriamycin and other quinones having antitumor activity. *Biochem Biophys Res Commun* 1974;58:633-638.
54. Gaby AR. The role of coenzyme Q10 in clinical medicine. Part II. Cardiovascular disease, hypertension, diabetes mellitus and infertility. *Altern Med Rev* 1996;1:168-175.
55. Hayek ER, Speakman E, Rehms E. Acute doxorubicin cardiotoxicity. *N Engl J Med* 2005;352:2456-2457.
56. Brouwer CA, Gietema JA, van den Berg MP et al. Long-term cardiac follow-up in survivors of a malignant bone tumour. *Ann Oncol* 2006;17:1586-1591.

Citations and Reference Literature: Coenzyme Q10

57. Folkers K, Wolaniuk A. Research on coenzyme Q10 in clinical medicine and in immunomodulation. *Drugs Exp Clin Res* 1985;11:539-545.
58. Domae N, Sawada H, Matsuyama E et al. Cardiomyopathy and other chronic toxic effects induced in rabbits by doxorubicin and possible prevention by coenzyme Q10. *Cancer Treat Rep* 1981;65:79-91.
59. Shinozawa S, Gomita Y, Araki Y. Protective effects of various drugs on Adriamycin (doxorubicin)-induced toxicity and microsomal lipid peroxidation in mice and rats. *Biol Pharm Bull* 1993;16:1114-1117.
60. Combs AB, Choe JY, Truong DH, Folkers K. Reduction by coenzyme Q10 of the acute toxicity of Adriamycin in mice. *Res Commun Chem Pathol Pharmacol* 1977;18:565-568.
61. Folkers K, Choe JY, Combs AB. Rescue by coenzyme Q10 from electrocardiographic abnormalities caused by the toxicity of Adriamycin in the rat. *Proc Natl Acad Sci U S A* 1978;75:5178-5180.
62. Choe JY, Combs AB, Saji S, Folkers K. Study of the combined and separate administration of doxorubicin and coenzyme Q10 on mouse cardiac enzymes. *Res Commun Chem Pathol Pharmacol* 1979;24:595-598.
63. Choe JY, Combs AB, Folkers K. Prevention by coenzyme Q10 of the electrocardiographic changes induced by Adriamycin in rats. *Res Commun Chem Pathol Pharmacol* 1979;23:199-202.
64. Lubawy WC, Dallam RA, Hurley LH. Protection against anthramycin-induced toxicity in mice by coenzyme Q10. *J Natl Cancer Inst* 1980;64:105-109.
65. Shaeffer J, El-Mahdi AM, Nichols RK. Coenzyme Q10 and Adriamycin toxicity in mice. *Res Commun Chem Pathol Pharmacol* 1980;29:309-315.
66. Usui T, Ishikura H, Izumi Y et al. Possible prevention from the progression of cardiotoxicity in Adriamycin-treated rabbits by coenzyme Q10. *Toxicol Lett* 1982;12:75-82.
67. Shinozawa S, Kawasaki H, Gomita Y. [Effect of biological membrane stabilizing drugs (coenzyme Q10, dextran sulfate and reduced glutathione) on Adriamycin (doxorubicin)-induced toxicity and microsomal lipid peroxidation in mice]. *Gan To Kagaku Ryoho* 1996;23:93-98.
68. Shinozawa S, Gomita Y, Araki Y. Tissue concentration of doxorubicin (Adriamycin) in mouse pretreated with alpha-tocopherol or coenzyme Q10. *Acta Med Okayama* 1991;45:195-199.
69. Neri B, Neri GC, Bandinelli M. Differences between carnitine derivatives and coenzyme Q10 in preventing in vitro doxorubicin-related cardiac damages. *Oncology* 1988;45:242-246.
70. Ronca-Testoni S, Zucchi R, Ronca F, Bertelli A. Effect of carnitine and coenzyme Q10 on the calcium uptake in heart sarcoplasmic reticulum of rats treated with anthracyclines. *Drugs Exp Clin Res* 1992;18:437-442.
71. Iarussi D, Auricchio U, Agretto A et al. Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. *Mol Aspects Med* 1994;15 Suppl:s207-s212.
72. Folkers K, Langsjoen P, Willis R et al. Lovastatin decreases coenzyme Q levels in humans. *Proc Natl Acad Sci U S A* 1990;87:8931-8934.
73. Watts GF, Castelluccio C, Rice-Evans C et al. Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin. *J Clin Pathol* 1993;46:1055-1057.
74. Ghirlanda G, Oradei A, Manto A et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. *J Clin Pharmacol* 1993;33:226-229.
75. De Pinieux G, Chariot P, Ammi-Said M et al. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. *Br J Clin Pharmacol* 1996;42:333-337.
76. Mortensen SA, Leth A, Agner E, Rohde M. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. *Mol Aspects Med* 1997;18 Suppl:S137-S144.
77. Silver MA, Langsjoen PH, Szabo S et al. Statin cardiomyopathy? A potential role for co-enzyme Q10 therapy for statin-induced changes in diastolic LV performance: description of a clinical protocol. *Biofactors* 2003;18:125-127.
78. Passi S, Stancato A, Aleo E et al. Statins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFA. *Biofactors* 2003;18:113-124.
79. Langsjoen PH, Langsjoen AM. The clinical use of HMG CoA-reductase inhibitors and the associated depletion of coenzyme Q10: a review of animal and human publications. *Biofactors* 2003;18:101-111.
80. Langsjoen PH, Folkers K, Lyson K et al. Pronounced increase of survival of patients with cardiomyopathy when treated with coenzyme Q10 and conventional therapy. *Int J Tissue React* 1990;12:163-168.
81. Manzoli U, Rossi E, Littarru GP et al. Coenzyme Q10 in dilated cardiomyopathy. *Int J Tissue React* 1990;12:173-178.
82. Sinatra ST. Refractory congestive heart failure successfully managed with high dose coenzyme Q10 administration. *Mol Aspects Med* 1997;18 Suppl:S299-S305.

Citations and Reference Literature: Coenzyme Q10

- 82a. Willis RA, Folkers K, Tucker JL, et al. Lovastatin decreases coenzyme Q levels in rats. *Proc Natl Acad Sci U S A* 1990;87(22):8928-8930.
83. Ichihara K, Satoh K, Yamamoto A, Hoshi K. [Are all HMG-CoA reductase inhibitors protective against ischemic heart disease?]. *Nippon Yakurigaku Zasshi* 1999;114 Suppl 1:142P-149P.
84. Rosenfeldt FL, Pepe S, Linnane A et al. Coenzyme Q10 protects the aging heart against stress: studies in rats, human tissues, and patients. *Ann NY Acad Sci* 2002;959:355-359; discussion 463-355.
85. Laaksonen R, Ojala JP, Tikkanen MJ, Himberg JJ. Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors. *Eur J Clin Pharmacol* 1994;46:313-317.
86. Paloma'ki A, Malminiemi K, Metsa-Ketela T. Enhanced oxidizability of ubiquinol and alpha-tocopherol during lovastatin treatment. *FEBS Lett* 1997;410:254-258.
87. Paloma'ki A, Malminiemi K, Solakivi T, Malminiemi O. Ubiquinone supplementation during lovastatin treatment: effect on LDL oxidation ex vivo. *J Lipid Res* 1998;39:1430-1437.
88. Bleske BE, Willis RA, Anthony M et al. The effect of pravastatin and atorvastatin on coenzyme Q10. *Am Heart J* 2001;142:E2.
89. Rundek T, Naini A, Sacco R et al. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. *Arch Neurol* 2004;61:889-892.
90. Yoshida H, Ishikawa T, Ayaori M et al. Effect of low-dose simvastatin on cholesterol levels, oxidative susceptibility, and antioxidant levels of low-density lipoproteins in patients with hypercholesterolemia: a pilot study. *Clin Ther* 1995;17:379-389.
91. Coghlan A. Vitamin E could reduce heart risk. *New Scientist* 1991;1770:24.
92. Bargossi AM, Battino M, Gaddi A et al. Exogenous CoQ10 preserves plasma ubiquinone levels in patients treated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. *Int J Clin Lab Res* 1994;24:171-176.
93. Miyake Y, Shouzu A, Nishikawa M et al. Effect of treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on serum coenzyme Q10 in diabetic patients. *Arzneimittelforschung* 1999;49:324-329.
94. Pettit FH, Harper RF, Vilaythong J et al. Reversal of statin toxicity to human lymphocytes in tissue culture. *Drug Metab Drug Interact* 2003;19:151-160.
95. Watts GF, Playford DA, Croft KD et al. Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in type II diabetes mellitus. *Diabetologia* 2002;45:420-426.
96. Title LM, Cummings PM, Giddens K et al. Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. *J Am Coll Cardiol* 2000;36:758-765.
97. White CM. Pharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation. *J Clin Pharmacol* 1999;39:111-118.
98. Wong B, Lumma WC, Smith AM et al. Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation. *J Leukoc Biol* 2001;69:959-962.
99. Brady AJB, Norrie J, Ford I. Statin prescribing: Is the reality meeting the expectations of primary care. *Br J Cardiol* 2005;12:397-400.
100. Goldman RE, Parker DR, Eaton CB et al. Patients' perceptions of cholesterol, cardiovascular disease risk, and risk communication strategies. *Ann Fam Med* 2006;4:205-212.
101. Brown MS. Coenzyme Q10 with HMG-CoA reductase inhibitors. Merck and Co (Rahway, NJ); 1990.
102. Tobert JA. Coenzyme Q10 with HMG-CoA reductase inhibitors. Merck and Co (Rahway, NJ); 1990.
103. Kishi T, Watanabe T, Folkers K. Bioenergetics in clinical medicine: prevention by forms of coenzyme Q of the inhibition by Adriamycin of coenzyme Q10-enzymes in mitochondria of the myocardium. *Proc Natl Acad Sci U S A* 1976;73:4653-4656.
104. Singh RB, Niaz MA, Rastogi SS et al. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. *J Hum Hypertens* 1999;13:203-208.
105. Hodgson JM, Watts GF, Playford DA et al. Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. *Eur J Clin Nutr* 2002;56:1137-1142.
106. Glassman AH, Roose SP. Risks of antidepressants in the elderly: tricyclic antidepressants and arrhythmia-revising risks. *Gerontology* 1994;40 Suppl 1:15-20.
107. Seahill L, Lynch KA. Tricyclic antidepressants: cardiac effects and clinical implications. *J Child Adolesc Psychiatr Nurs* 1994;7:37-39.
108. Pinto J, Huang YP, Pelliccione N, Rivlin RS. Cardiac sensitivity to the inhibitory effects of chlorpromazine, imipramine and amitriptyline upon formation of flavins. *Biochem Pharmacol* 1982;31:3495-3499.
109. Morton RA. Ubiquinones, plastoquinones and vitamins K. *Biol Rev Camb Philos Soc* 1971;46:47-96.

Citations and Reference Literature: Coenzyme Q10

110. Combs AB, Porter TH, Folkers K. Anticoagulant activity of a naphthoquinone analog of vitamin K and an inhibitor of coenzyme Q10-enzyme systems. *Res Commun Chem Pathol Pharmacol* 1976;13:109-114.
111. Spigset O. Reduced effect of warfarin caused by ubidecarenone. *Lancet* 1994;344:1372-1373.
112. Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. *Ugeskr Laeger* 1998;160:3226-3227.
113. Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. *Am J Health Syst Pharm* 2000;57:1221-1227; quiz 1228-1230.
- 113a. Engelsen J, Nielsen JD, Hansen KF. [Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial] *Ugeskr Laeger* 2003;165(18):1868-71. [Danish]
114. Linder MW. Genetic mechanisms for hypersensitivity and resistance to the anticoagulant warfarin. *Clin Chim Acta* 2001;308:9-15.
115. Aberg F, Appelkvist EL, Broijersén A et al. Gemfibrozil-induced decrease in serum ubiquinone and alpha- and gamma-tocopherol levels in men with combined hyperlipidaemia. *Eur J Clin Invest* 1998;28:235-242.
116. Kotake C, Ito Y, Yokoyama M, Fukuzaki H. Protective effect of coenzyme Q10 on thyrotoxic heart in rabbits. *Heart Vessels* 1987;3:84-90.
117. Mancini A, De Marinis L, Calabro F et al. Evaluation of metabolic status in amiodarone-induced thyroid disorders: plasma coenzyme Q10 determination. *J Endocrinol Invest* 1989;12:511-516.
118. Portakal O, Inal-Erden M. Effects of pentoxifylline and coenzyme Q10 in hepatic ischemia/reperfusion injury. *Clin Biochem* 1999;32:461-466.
119. Lund EL, Quistorff B, Spang-Thomsen M, Kristjansen PE. Effect of radiation therapy on small-cell lung cancer is reduced by ubiquinone intake. *Folia Microbiol (Praha)* 1998;43:505-506.
120. Rosenfeldt FL, Mijch A, McCrystal G et al. Skeletal myopathy associated with nucleoside reverse transcriptase inhibitor therapy: potential benefit of coenzyme Q10 therapy. *Int J STD AIDS* 2005;16:827-829.
121. Willis R, Anthony M, Sun L et al. Clinical implications of the correlation between coenzyme Q10 and vitamin B6 status. *Biofactors* 1999;9:359-363.
122. Kagan VE, Fabisak JP, Tyurina YY. Independent and concerted antioxidant functions of coenzyme Q. In: Kagan VE, Quinn PJ, eds. *Coenzyme Q: Molecular Mechanisms in Health and Disease*. Boca Raton, Fla: CRC Press; 2001:119-130.
123. Thomas SR, Stocker R. Mechanisms of antioxidant action of ubiquinol-10 for low-density lipoprotein. In: Kagan VE, Quinn PJ, eds. *Coenzyme Q: Molecular Mechanisms in Health and Disease*. Boca Raton, Fla: CRC Press; 2001:131-150.
124. Lister RE. An open, pilot study to evaluate the potential benefits of coenzyme Q10 combined with Ginkgo biloba extract in fibromyalgia syndrome. *J Int Med Res* 2002;30:195-199.

Reference Literature

- [No authors listed.] Xenical (orlistat), product prescribing information. Nutley, NJ: Roche Laboratories, Inc; 2000.
- [No authors listed.] Product review: co-enzyme Q10. Available at <http://www.consumerlab.com>. Accessed January 30, 2004.
- Albano CB, Muralikrishnan D, Ebadi M. Distribution of coenzyme Q homologues in brain. *Neurochem Res* 2002;27(5):359-368.
- Alcolado JC, Laji K, Gill-Randall R. Maternal transmission of diabetes. *Diabet Med* 2002;19(2):89-98.
- Alho H, Lonnrot K. Coenzyme Q supplementation and longevity. In: Kagan VE, Quinn PJ, eds. *Coenzyme Q: molecular mechanisms in health and disease*. Boca Raton, FL: CRC Press; 2001:371-380.
- Alsheikh-Ali AA, Ambrose MS, Kuvin JT, et al. The safety of rosuvastatin as used in common clinical practice. a postmarketing analysis. *Circulation* 2005;111(23):3051-3057.
- Arnett DK, Jacobs DR Jr, Luepker RV, et al. Twenty-year trends in serum cholesterol, hypercholesterolemia, and cholesterol medication use: the Minnesota Heart Survey, 1980-1982 to 2000-2002. *Circulation* 2005;112:3884-3891.
- Artuch R, Colome C, Vilaseca MA, et al. Plasma phenylalanine is associated with decreased serum ubiquinone-10 concentrations in phenylketonuria. *J Inher Metab Dis* 2001;24(3):359-366.
- Artuch R, Vilaseca MA, Moreno J, et al. Decreased serum ubiquinone-10 concentrations in phenylketonuria. *Am J Clin Nutr* 1999;70:892-895.
- Baggio E, Gandini R, Plancher AC, et al. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure: CoQ10 Drug Surveillance Investigators. *Mol Aspects Med* 1994;15(Suppl):s287-s294.
- Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. *Lancet* 2005;366(9493):1267-1278. Erratum in *Lancet* 2005;366(9494):1358.
- Bairey Merz CN. The treatment of hypercholesterolemia beyond statin therapy: American Heart Association Scientific Sessions 2005. Dallas; AHA; 2005.

Citations and Reference Literature: Coenzyme Q10

- Balercia G, Arnaldi G, Lucarelli G, et al. Effects of exogenous CoQ10 administration in patients with idiopathic asthenozoospermia. *Int J Andrology* 2000;(Suppl 23):43.
- Balercia G, Mosca F, Mantero F, et al. Coenzyme q10 supplementation in infertile men with idiopathic asthenozoospermia: an open, uncontrolled pilot study. *Fertil Steril* 2004;81:93-98.
- Bargossi AM, Grossi G, Fiorella PL, et al. Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors. *Mol Aspects Med* 1994;15(Suppl):s187-s193.
- Battino M, Giunta S, Galeazzi L, et al. Coenzyme Q10, antioxidant status and ApoE isoforms. *Biofactors* 2003;18(1-4):299-305.
- Battino M, Bompadre S, Leone L, et al. Coenzyme Q, vitamin E and Apo-E alleles in Alzheimer disease. *Biofactors* 2003;18(1-4):277-281.
- Battino M, Bompadre S, Leone L, et al. The effect of Cyclosporine A chronic administration on the antioxidant pattern of rat liver mitochondria: structural and functional consequences. *Biofactors* 2003;18(1-4):271-275.
- Beal MF. Coenzyme Q10 as a possible treatment for neurodegenerative diseases. *Free Radic Res* 2002;36(4):455-460.
- Beckman KB, Ames BN. Mitochondrial aging: open questions. *Ann N Y Acad Sci* 1998;854:118-127.
- Belardinelli R, Mucaj A, Lacalaprice F, et al. Coenzyme Q10 and exercise training in chronic heart failure. *Eur Heart J* 2006;27(22):2675-2681.
- Berthold HK, Unverdorben S, Ralf Degenhardt R, et al. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. *JAMA* 2006;295:2262-2269.
- Beyer RE. An analysis of the role of coenzyme Q in free radical generation, and as an antioxidant. *Biochem Cell Biol* 1992;70(6):390-403. (Review)
- Beyer RE. The role of ascorbate in antioxidant protection of biomembranes: interaction with vitamin E and coenzyme Q. *J Bioenerg Biomembr* 1994;26(4):349-358. (Review)
- Bianchi A, Salomone S, Caraci F, et al. Role of magnesium, coenzyme Q10, riboflavin, and vitamin B12 in migraine prophylaxis. *Vitam Horm* 2004;69:297-312. (Review)
- Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. *Hepatology* 2005;42(2):481-489.
- Blasi MA, Bovina C, Carella G, et al. Does coenzyme Q10 play a role in opposing oxidative stress in patients with age-related macular degeneration? *Ophthalmologica* 2001;215(1):51-54.
- Block KI. Why integrative therapies? *Integr Cancer Ther* 2006;5(1):53-56. (Editorial)
- Boitier E, Degoul F, Desguerre I, et al. A case of mitochondrial encephalomyopathy associated with a muscle coenzyme Q10 deficiency. *J Neurol Sci* 1998;156(1):41-46.
- Bonetti A, Solito F, Carmosino G, et al. Effect of ubiquinol oral treatment on aerobic power in middle-aged trained subjects. *J Sports Med Phys Fitness* 2000;40(1):51-57.
- Bottorff M, Hansten P. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: the role of metabolism: monograph for physicians. *Arch Intern Med* 2000;160:2273-2280.
- Braun B, Clarkson PM, Freedson PS, et al. Effects of coenzyme Q10 supplementation on exercise performance, VO2max, and lipid peroxidation in trained cyclists. *Int J Sport Nutr* 1991;1(4):353-365.
- Bresolin N, Doriguzzi C, Ponzetto C, et al. Ubidecarenone in the treatment of mitochondrial myopathies: a multi-center double-blind trial. *J Neurol Sci* 1990;100(1-2):70-78.
- Britt LD. Coenzyme Q10 confers cardiovascular prevention. *Shock* 2005;24(6):597.
- Brüge F, Tiano L, Cacciamani T, et al. Effect of UV-C mediated oxidative stress in leukemia cell lines and its relation to ubiquinone content. *Biofactors* 2003;18(1-4):51-63.
- Buhmann C, Arlt S, Kontush A, et al. Plasma and CSF markers of oxidative stress are increased in Parkinson's disease and influenced by antiparkinsonian medication. *Neurobiol Dis* 2004;15(1):160-170.
- Burke BE, Neuenschwander R, Olson RD. Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in isolated systolic hypertension. *South Med J* 2001;94(11):1112-1117.
- Calabro P, Yeh ET. The pleiotropic effects of statins. *Curr Opin Cardiol* 2005;20(6):541-546.
- Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med* April 8, 2004;350(15):1495-1504.
- Chagan L, Ioselovich A, Asherova L, et al. Use of alternative pharmacotherapy in management of cardiovascular diseases. *Am J Manag Care* 2002;8(3):270-288. (Review)
- Chalasani N, Aljadhey H, Kesterson J, et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. *Gastroenterology* 2004;126(5):1287-1292.

Citations and Reference Literature: Coenzyme Q10

- Chan DC, Watts GF, Nguyen MN, et al. Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity. *Am J Clin Nutr* 2006;84(1):37-43.
- Chan DC, Watts GF, Barrett PH, et al. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. *Diabetes* 2002;51(8):2377-2386.
- Chello M, Mastroroberto P, Romano R, et al. Protection by coenzyme Q10 from myocardial reperfusion injury during coronary artery bypass grafting. *Ann Thorac Surg* 1994;58(5):1427-1432.
- Chen RS, Huang CC, Chu NS. Coenzyme Q10 treatment in mitochondrial encephalomyopathies: short-term double-blind, crossover study. *Eur Neurol* 1997;37(4):212-218.
- Chen YF, Lin YT, Wu SC. Effectiveness of coenzyme Q10 on myocardial preservation during hypothermic cardioplegic arrest. *J Thorac Cardiovasc Surg* 1994;107(1):242-247.
- Chipperfield B. Ubiquinone concentrations in tumours and some normal tissues in man. *Nature* 1966;209(5029):1207-1209.
- Cooper JM, Schapira AH. Friedreich's ataxia: disease mechanisms, antioxidant and coenzyme Q10 therapy. *Biofactors* 2003;18(1-4):163-171.
- Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. *N Engl J Med* 2005;352(23):2389-2397.
- Crane FL. Biochemical functions of coenzyme Q10. *J Am Coll Nutr* 2001;20(6):591-598.
- Danysz A, Oledzka K, Bukowska-Kiliszek M. Influence of coenzyme Q-10 on the hypotensive effects of enalapril and nitrendipine in spontaneously hypertensive rats. *Pol J Pharmacol* 1994;46(5):457-461.
- Davison GW, Hughes CM, Bell RA. Exercise and mononuclear cell DNA damage: the effects of antioxidant supplementation. *Int J Sport Nutr Exerc Metab* 2005;15(5):480-492.
- de Bustos F, Jimenez-Jimenez FJ, Molina JA, et al. Serum levels of coenzyme Q10 in patients with multiple sclerosis. *Acta Neurol Scand* 2000;101(3):209-211.
- Demirbag R, Yilmaz R, Erel O, et al. The relationship between potency of oxidative stress and severity of dilated cardiomyopathy. *Can J Cardiol* 2005;21(10):851-855.
- Digiesi V, Cantini F, Brodbeck B. Effect of coenzyme Q10 on essential arterial hypertension. *Curr Ther Res* 1990;47(5):841-845.
- Digiesi V, Cantini F, Oradei A, et al. Q10 in essential hypertension. *Mol Aspects Med* 1994;15(Suppl):s257-s263.
- DiMauro S, Gurgel-Giannetti J. The expanding phenotype of mitochondrial myopathy. *Curr Opin Neurol* 2005;18(5):538-542.
- Donchenko HV, Chahovets' RV. Changes in ubiquinone content of the liver caused by cortisone acetate in normal and vitamin A-deficient rats. *Fed Proc Transl Suppl* 1965;24(6):983-985.
- Dreon DM, Krauss RM. Diet-gene interactions in human lipoprotein metabolism. *J Am Coll Nutr* 1997;16:313-324.
- Duncan AJ, Heales SJ, Mills K, et al. Determination of coenzyme q10 status in blood mononuclear cells, skeletal muscle, and plasma by HPLC with di-propoxy-coenzyme q10 as an internal standard. *Clin Chem* 2005;51(12):2380-2382.
- Eaton S, Skinner R, Hale JP, et al. Plasma coenzyme Q(10) in children and adolescents undergoing doxorubicin therapy. *Clin Chim Acta* 2000;302(1-2):1-9.
- Ebadi M, Govitrapong P, Sharma S, et al. Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of parkinson's disease. *Biol Signals Recept* 2001;10(3-4):224-253. (Review)
- Ebadi M, Muralikrishnan D, Pellett LJ, et al. Ubiquinone (coenzyme Q10) and complex I in mitochondrial oxidative disorder of Parkinson's disease. *Proc West Pharmacol Soc* 2000;43:55-63. (Review)
- Ebadi M, Sharma S, Muralikrishnan D, et al. Metallothionein provides ubiquinone-mediated neuroprotection in Parkinson's disease. *Proc West Pharmacol Soc* 2002;45:36-38. (Review)
- Engelsen J, Nielsen JD, Hansen KF. [Effect of coenzyme Q10 and ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment: a randomized, double-blind, placebo-controlled cross-over trial.] *Ugeskr Laeger* 2003;165(18):1868-1871. [Danish]
- Engelsen J, Nielsen JD, Winther K. Effect of coenzyme Q10 and ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients: a randomised, double blind, placebo-crossover trial. *Thromb Haemost* 2002;87(6):1075-1076.
- Eriksson JG, Forsen TJ, Mortensen SA, et al. The effect of coenzyme Q10 administration on metabolic control in patients with type 2 diabetes mellitus. *Biofactors* 1999;9(2-4):315-318.
- Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. *Biochim Biophys Acta* 1995;1271(1):195-204.
- Farnier M, DeJager S, for the French Fluvastatin Study Group. Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. *Am J Cardiol* 2000;85:53-57.
- Ferrante KL, Shefner J, Zhang H, et al. Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. *Neurology* 2005;65(11):1834-1836.

Citations and Reference Literature: Coenzyme Q10

- Folkers K. Basic chemical research on coenzyme Q10 and integrated clinical research on therapy of diseases. In: G Lenaz, ed. Coenzyme Q. New York: John Wiley and Sons; 1985.
- Folkers K, Brown R, Judy WV, et al. Survival of cancer patients on therapy with coenzyme Q10. *Biochem Biophys Res Commun* 1993;192(1):241-245. (Review)
- Folkers K, Drzewoski J, Richardson PC, et al. Bioenergetics in clinical medicine: XVI: reduction of hypertension in patients by therapy with coenzyme Q10. *Res Commun Chem Pathol Pharmacol* 1981;31(1):129-140.
- Folkers K, Kaji M, Baker L, et al. Cardiac outputs of control individuals and cancer patients and evidence of deficiencies of coenzyme Q10 and vitamin B6. *Res Commun Chem Pathol Pharmacol* 1980;28(1):145-152.
- Folkers K, Langsjoen P. Prevention by CoQ10 of life-threatening cardiac dysfunction as a side effect of treatment of hypercholesterolemia by lovastatin in normal medical practice. In: Folkers K, Littarru GP, Yamagami T, Eds. *Biochemical and Clinical Aspects of Coenzyme Q*, Volume 6. Amsterdam: Elsevier Science 1991:449-452.
- Folkers K, Osterborg A, Nylander M, et al. Activities of vitamin Q10 in animal models and a serious deficiency in patients with cancer. *Biochem Biophys Res Commun* 1997;234(2):296-299.
- Folkers K, Shizukuishi S, Takemura K, et al. Increase in levels of IgG in serum of patients treated with coenzyme Q10. *Res Commun Pathol Pharmacol* 1982;38(2):335-338.
- Folkers K, Simonsen R. Two successful double-blind trials with coenzyme Q 10 (vitamin Q 10) on muscular dystrophies and neurogenic atrophies. *Biochim Biophys Acta* 1995;1271(1):281-286.
- Folkers K, Vadhanavikit S, Mortensen SA. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10. *Proc Natl Acad Sci U S A* 1985;82(3):901-904.
- Folkers K, Wolaniuk J, Simonsen R, et al. Biochemical rationale and the cardiac response of patients with muscle disease to therapy with coenzyme Q10. *Proc Natl Acad Sci U S A* 1985;82:4513-4516.
- Foody JM, Shah R, Galusha D, et al. Statins and mortality among elderly patients hospitalized with heart failure. *Circulation* 2006;113(8):1086-1092.
- Fujimoto S, Kurihara N, Hirata K, et al. Effects of coenzyme Q10 administration on pulmonary function and exercise performance in patients with chronic lung diseases. *Clin Invest* 1993;71(8 Suppl):S162-S166.
- Fujioka T, Sakamoto Y, Mimura G. Clinical study of cardiac arrhythmias using a 24-hour continuous electrocardiographic recorder (5th report): antiarrhythmic action of coenzyme Q10 in diabetics. *Tohoku J Exp Med* 1983;141(Suppl):453-463.
- Fuke C, Krikorian SA, Couris RR. Coenzyme Q 10: a review of essential functions and clinical trials. *U S Pharmacist* 2000;25(10):28-41.
- Gaby AR. The role of coenzyme Q10 in clinical medicine: part II: cardiovascular disease, hypertension, diabetes mellitus and infertility. *Altern Med Rev* 1996;1:168-175. (Review)
- Garewal HS. Antioxidants and disease prevention. New York: CRC Press; 1997:19-26.
- Gazdikova K, Gvozdjakova A, Kucharska J, et al. Effect of coenzyme Q10 in patients with kidney diseases. *Cas Lek Cesk* 2000;140:307-310.
- Getz L, Sigurdsson JA, Hetlevik I, et al. Estimating the high risk group for cardiovascular disease in the Norwegian HUNT 2 population according to the 2003 European guidelines: modelling study. *BMJ* 2005;331(7516):551.
- Glassman AH, Roose SP. Risks of antidepressants in the elderly: tricyclic antidepressants and arrhythmia-revising risks. *Gerontology* 1994;40(Suppl 1):15-20.
- Go AS, Iribarren C, Chandra M, et al. Statin and beta-blocker therapy and the initial presentation of coronary heart disease. *Ann Intern Med* 2006;144(4):229-238.
- Go AS, Lee WY, Yang J, et al. Statin therapy and risks for death and hospitalization in chronic heart failure. *JAMA* 2006;296 2105-2111.
- Goldberg AC, Ostlund RE Jr, Bateman JH, et al. Effect of plant stanol tablets on low-density lipoprotein cholesterol lowering in patients on statin drugs. *Am J Cardiol* 2006;97(3):376-379.
- Goldman RE, Parker DR, Eaton CB, et al. Patients' perceptions of cholesterol, cardiovascular disease risk, and risk communication strategies. *Ann Fam Med* 2006;4(3):205-212.
- Golomb BA. Implications of statin adverse effects in the elderly. *Expert Opin Drug Saf* 2005;4(3):389-397.
- Golomb BA, Criqui MH, White H, et al. Conceptual foundations of the UCSD Statin Study: a randomized controlled trial assessing the impact of statins on cognition, behavior, and biochemistry. *Arch Intern Med* 2004;164(2):153-162. (Review)
- Golomb BA, Criqui MH, White HL, et al. The UCSD Statin Study: a randomized controlled trial assessing the impact of statins on selected noncardiac outcomes. *Control Clin Trials* 2004;25(2):178-202.
- Golomb BA, Kane T, Dimsdale JE. Severe irritability associated with statin cholesterol-lowering drugs. *QJM* 2004;97(4):229-235.
- Gorinstein S, Caspi A, Libman I, et al. Red grapefruit positively influences serum triglyceride level in patients suffering from coronary atherosclerosis: studies in vitro and in humans. *J Agric Food Chem* 2006;54(5):1887-1892.

Citations and Reference Literature: Coenzyme Q10

- Gotz ME, Gerstner A, Harth R, et al. Altered redox state of platelet coenzyme Q10 in Parkinson's disease. *J Neural Transm* 2000;107(1): 41-48.
- Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. *JAMA* 2004;292:2585-2590.
- Greenberg SM, Frishman WH. Coenzyme Q10: a new drug for myocardial ischemia? *Med Clin North Am* 1988;72(1):243-258. (Review)
- Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. *J Am Coll Cardiol* 2004;44(3):720-732. (Review)
- Grundy SM. The issue of statin safety. where do we stand? *Circulation* 2005. Epub ahead of print. (Editorial)
- Gutzmann H, Hadler D. Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study. *J Neural Transm Suppl* 1998;54:301-310.
- Haga SB, Burke W. Using pharmacogenetics to improve drug safety and efficacy. *JAMA* 2004;291:2869-2871. (Editorial)
- Hamada M, Kazatain Y, Ochi T, et al. Correlation between serum CoQ10 level and myocardial contractility in hypertensive patients. In: Folkers K, Yamamura Y, eds. *Biomedical and clinical aspects of coenzyme Q*. Vol 4. Amsterdam: Elsevier; 1984:263-270.
- Hanioka T, Tanaka M, Ojima M, et al. Effect of topical application of coenzyme Q10 on adult periodontitis. *Mol Aspects Med* 1994;15(Suppl):s241-s248.
- Hanisch F, Zierz S. Only transient increase of serum CoQ subset 10 during long-term CoQ10 therapy in mitochondrial ophthalmoplegia. *Eur J Med Res* 2003;8(11):485-491.
- Hansen IL, Iwamoto Y, Kishi T, et al. Bioenergetics in clinical medicine: IX: gingival and leucocytic deficiencies of coenzyme Q 10 in patients with periodontal disease. *Res Commun Chem Pathol Pharmacol* 1976;14(4):729-738.
- Hansen KE, Hildebrand JP, Ferguson EE, et al. Outcomes in 45 patients with statin-associated myopathy. *Arch Intern Med* 2005;165:2671-2676.
- Hasegawa G, Yamamoto Y, Zhi JG, et al. Daily profile of plasma %CoQ10 level, a biomarker of oxidative stress, in patients with diabetes manifesting postprandial hyperglycaemia. *Acta Diabetol* 2005;42(4):179-181.
- Hata S, Kunida H, Oyama Y. [Antihypertensive effects of coenzyme Q10 in essential hypertension: in relation to the renin-aldosterone system.] *Horumon To Rinsho* 1977;25(9):1019-1023. [Japanese]
- Hayek ER et al. Acute doxorubicin cardiotoxicity. *N Engl J Med* 2005;352(23):2456-2457.
- Heller JH. Disease, the host defense, and Q-10. *Perspect Biol Med* 1973;16(2):181-187.
- Henriksen JE, Andersen CB, Hother-Nielsen O, et al. Impact of ubiquinone (coenzyme Q10) treatment on glycaemic control, insulin requirement and well-being in patients with type 1 diabetes mellitus. *Diabet Med* 1999;16(4):312-318.
- Hodges S, Hertz N, Lockwood K, et al. CoQ10: could it have a role in cancer management? *Biofactors* 1999;9(2-4):365-370.
- Hodgson JM, Watts GF. Can coenzyme Q10 improve vascular function and blood pressure? Potential for effective therapeutic reduction in vascular oxidative stress. *Biofactors* 2003;18(1-4):129-136.
- Hodgson JM, Watts GF, Playford DA, et al. Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. *Eur J Clin Nutr* 2002;56(11):1137-1142.
- Hofman-Bang C, Rehnqvist N, Swedberg K, et al. Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure: the Q10 Study Group. *J Card Fail* 1995;1(2):101-107.
- Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. *Arch Intern Med* 2005;165:1095-1106.
- Horvath R, Schneiderat P, Schoser BG, et al. Coenzyme Q10 deficiency and isolated myopathy. *Neurology* 2006;66(2):253-255.
- Hovingh GK, Brownlie A, Bisoendial RJ, et al. A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease. *J Am Coll Cardiol* 2004;44(7):1429-1435.
- Hsu CH, Cui Z, Mumper RJ, et al. Preparation and characterization of novel coenzyme Q10 nanoparticles engineered from microemulsion precursors. *AAPS PharmSciTech* 2003;4(3):E32.
- Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. *Neurology* 2001;57(3):397-404.
- Ikematsu H, Nakamura K, Harashima S, et al. Safety assessment of coenzyme Q10 (Kaneka Q10) in healthy subjects: a double-blind, randomized, placebo-controlled trial. *Regul Toxicol Pharmacol* 2006;44(3):212-218.
- Imagawa M, Naruse S, Tsuji S, et al. Coenzyme Q10, iron, and vitamin B6 in genetically-confirmed Alzheimer's disease. *Lancet* 1992;340:671. (Letter)

Citations and Reference Literature: Coenzyme Q10

- Iribarren C, Folsom AR, Jacobs DR Jr, et al. Association of serum vitamin levels, LDL susceptibility to oxidation, and autoantibodies against MDA-LDL with carotid atherosclerosis: a case-control study: the ARIC Study Investigators: Atherosclerosis Risk in Communities. *Arterioscler Thromb Vasc Biol* 1997;17(6):1171-1177.
- Iribarren C, Belcher JD, Jacobs DR Jr, et al. Relationship of lipoproteins, apolipoproteins, triglycerides and lipid ratios to plasma total cholesterol in young adults: the CARDIA Study: Coronary Artery Risk Development in Young Adults. *J Cardiovasc Risk* 1996;3(4):391-396.
- Iribarren C, Jacobs DR, Sadler M, et al. Hemorrhagic stroke: is the association confined to elderly men? The Kaiser Permanente Medical Care Program. *Stroke* 1996;27(11):1993-1998.
- Iribarren C, Jacobs DR Jr, Sidney S, et al. Cohort study of serum total cholesterol and in-hospital incidence of infectious diseases. *Epidemiol Infect* 1998;121(2):335-347.
- Iribarren C, Jacobs DR Jr, Sidney S, et al. Serum total cholesterol and risk of hospitalization, and death from respiratory disease. *Int J Epidemiol* 1997;26(6):1191-1202.
- Iribarren C, Jacobs DR Jr, Slattery ML, et al. Epidemiology of low total plasma cholesterol concentration among young adults: the CARDIA study: Coronary Artery Risk Development in Young Adults. *Prev Med* 1997;26(4):495-507.
- Iribarren C, Reed DM, Burchfiel CM, et al. Serum total cholesterol and mortality: confounding factors and risk modification in Japanese-American men. *JAMA* 1995;273(24):1926-1932.
- Iribarren C, Reed DM, Chen R, et al. Low serum cholesterol and mortality: which is the cause and which is the effect? *Circulation* 1995;92(9):2396-2403.
- Iribarren C, Reed DM, Wergowske G, et al. Serum cholesterol level and mortality due to suicide and trauma in the Honolulu Heart Program. *Arch Intern Med* 1995;155(7):695-700.
- Iribarren C, Sharp D, Burchfiel CM, et al. Association of serum total cholesterol with coronary disease and all-cause mortality: multivariate correction for bias due to measurement error. *Am J Epidemiol* 1996;143(5):463-471.
- Ishiyama T, Morita Y, Toyama S, et al. A clinical study of the effect of coenzyme Q on congestive heart failure. *Jpn Heart J* 1976;17(1):32-42.
- Istvan ES, Deisenhofer J. Structural mechanisms for statin inhibition of HMG-CoA reductase. *Science* 2001;292:1160-1164.
- Jackson PR, Wallis EJ, Haq IU, et al. Statins for primary prevention: at what coronary risk is safety assured? *Br J Clin Pharmacol* 2001;52(4):439-446.
- Jacobs DR Jr, Hebert B, Schreiner PJ, et al. Reduced cholesterol is associated with recent minor illness: the CARDIA Study: Coronary Artery Risk Development in Young Adults. *Am J Epidemiol* 1997;146(7):558-564.
- Jenkins DJ, Kendall CW, Marchie A, et al. The effect of combining plant sterols, soy protein, viscous fibers, and almonds in treating hypercholesterolemia. *Metabolism* 2003;52(11):1478-1483.
- Jimenez-Jimenez FJ, Molina JA, de Bustos F, et al. Serum levels of coenzyme Q10 in patients with Parkinson's disease. *J Neural Transm* 2000;107(2):177-181.
- Jolliet P, Simon N, Barre J, et al. Plasma coenzyme Q10 concentrations in breast cancer: prognosis and therapeutic consequences. *Int J Clin Pharmacol Therapeut* 1998;36:506-509.
- Judy WV, Hall JH, Dugan W, et al. Coenzyme Q10 reduction of Adriamycin® cardiotoxicity. In Folkers K, Yamamura Y, eds. *Biomedical and clinical aspects of coenzyme Q*. Vol. 4. Amsterdam: Elsevier/North Holland Biomedical Press; 1984:231-241.
- Judy WV. Nutritional intervention in cancer prevention and treatment. American College for Advancement in Medicine Spring Conference. Ft Lauderdale, FL, May 3, 1998.
- Judy WV, Stogsdill WW, Folkers K. Myocardial preservation by therapy with coenzyme Q10 during heart surgery. *Clin Investig* 1993;71(8 Suppl):S155-S161.
- Kagan VE, Fabisak JP, Tyurina YY. Independent and concerted antioxidant functions of coenzyme Q. In: Kagan VE, Quinn PJ, eds. *Coenzyme Q: molecular mechanisms in health and disease*. Boca Raton, FL: CRC Press; 2001:119-130.
- Kaikkonen J, Tuomainen TP, Nyyssönen K, et al. Coenzyme Q10: absorption, antioxidative properties, determinants, and plasma levels. *Free Radic Res* 2002;36(4):389-397.
- Kamei M, Fujita T, Kanbe T, et al. The distribution and content of ubiquinone in foods. *Int J Vitam Nutr Res* 1986;56(1):57-63.
- Kamikawa T, Kobayashi A, Yamashita T, et al. Effects of coenzyme Q10 on exercise tolerance in chronic stable angina pectoris. *Am J Cardiol* 1985;56(4):247-251.
- Kaplan RM, Golomb BA. Cost-effectiveness of statin medications. *Am Psychol* 2001;56(4):366-367.
- Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. *Circulation* 2006;114(25):2788-2797.
- Kavey R-EW, Allada V, Daniels SR, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the

Citations and Reference Literature: Coenzyme Q10

- Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. *Circulation* 2006;114:2710-2738.
- Kelly GS. Sport nutrition: a review of selected nutritional supplements for endurance athletes. *Altern Med Rev* 1997;2:282-295. (Review)
- Kelso GF, Porteous CM, Coulter CV, et al. Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. *J Biol Chem* 2001;276(7):4588-4596.
- Kerns W II, Kline J, Ford MD. Blocker and calcium channel blocker toxicity. *Emerg Med Clin North Am* 1994;12:2:365-390.
- Khatta M, Alexander BS, Krichten CM, et al. The effect of coenzyme Q10 in patients with congestive heart failure. *Ann Intern Med* 2000;132:636-640.
- Kishi H, Kishi T, Folkers K. Bioenergetics in clinical medicine: III: inhibition of coenzyme Q10-enzymes by clinically used anti-hypertensive drugs. *Res Commun Chem Pathol Pharmacol* 1975;12(3):533-540.
- Kishi T, Kishi H, Watanabe T, et al. Bioenergetics in clinical medicine XI: studies on coenzyme Q and diabetes mellitus. *J Med* 1976;7(3-4):307-321.
- Kishi T, Makino K, Okamoto T, et al. Inhibition of myocardial respiration by psychotherapeutic drugs and prevention by coenzyme Q10. In: Yamamura Y, Folkers K, Ito Y, eds. *Biochemical and clinical aspects of coenzyme Q*. Vol 2. Amsterdam: Elsevier/North Holland Biomedical Press; 1980:139-157.
- Kishi T, Okamoto T, Takahashi T, et al. Cardiostimulatory action of coenzyme Q homologues on cultured myocardial cells and their biochemical mechanisms. *Clin Investig* 1993;71(8 Suppl):S71-S75.
- Kishi T, Watanabe T, Folkers K. Bioenergetics in clinical medicine XV: inhibition of coenzyme Q10-enzymes by clinically used adrenergic blockers of beta-receptors. *Res Commun Chem Pathol Pharmacol*. 1977;17(1):157-164.
- Kishi T, Watanabe T, Folkers K. Bioenergetics in clinical medicine: prevention by forms of coenzyme Q of the inhibition by adriamycin of coenzyme Q10-enzymes in mitochondria of the myocardium. *Proc Natl Acad Sci U S A* 1976;73(12):4653-4656.
- Knopp RH, d'Emden M, Smilde JG, et al. Efficacy and safety of Atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN). *Diabetes Care* 2006;29(7):1478-1485.
- Koehler CM, Beverly KN, Leverich EP. Redox pathways of the mitochondrion. *Antioxid Redox Signal* 2006;8(5-6):813-822. (Review)
- Kokawa T, Shiota K, Oda K, et al. Coenzyme Q 10 in cancer chemotherapy: experimental studies on augmentation of the effects of masked compounds, especially in the combined chemotherapy with immunopotentiators. *Gan To Kagaku Ryoho* 1983;10(3):768-774.
- Koroshetz WJ, Jenkins BG, Rosen BR, et al. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. *Ann Neurol* 1997;41(2):160-165.
- Krauss RM. Atherogenic lipoprotein phenotype and diet-gene interactions. *J Nutr* 2001;131(2):340S-3S. (Review)
- Krauss RM. Dietary and genetic probes of atherogenic dyslipidemia. *Arterioscler Thromb Vasc Biol* 2005;25(11):2265-2272.
- Krauss RM, Siri PW. Metabolic abnormalities: triglyceride and low-density lipoprotein. *Endocrinol Metab Clin North Am* 2004;33(2):405-415. (Review)
- Krauss RM, Yang H, Rieder MJ, et al. Haplotypes in the HMGCoA reductase gene influence plasma LDL level and LDL response to statin in African Americans and Caucasians: American Heart Association Scientific Sessions 2005: Dallas, TX; November 14, 2005. Abstract 725. *Circulation Suppl II* 2005;112(17):II-135. (Abstract)
- Kristiansen IS, Eggen AE, Thelle DS. Cost effectiveness of incremental programmes for lowering serum cholesterol concentration: is individual intervention worth while? *BMJ* 1991;302(6785):1119-1122.
- Kuklinski B, Weissenbacher E, Fahnrich A. Coenzyme Q10 and antioxidants in acute myocardial infarction. *Mol Aspects Med* 1994;15(Suppl):s143-s147.
- Kwiterovich PO Jr. Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity. *Am J Cardiol* 2002;90(8A):30i-47i. (Review)
- Laaksonen R, Fogelholm M, Himberg JJ, et al. Ubiquinone supplementation and exercise capacity in trained young and older men. *Eur J Appl Physiol Occup Physiol* 1995;72(1-2):95-100.
- Laaksonen R, Jokelainen K, Laakso J, et al. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. *Am J Cardiol* 1996;77(10):851-854.
- Laaksonen R, Jokelainen K, Sahi T, et al. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. *Clin Pharmacol Ther* 1995;57:62-66.
- Lalani SR, Vladutiu GD, Plunkett K, et al. Isolated mitochondrial myopathy associated with muscle coenzyme Q10 deficiency. *Arch Neurol* 2005;62(2):317-320.
- Lamperti C, Naini A, Hirano M, et al. Cerebellar ataxia and coenzyme Q10 deficiency. *Neurology* 2003;60(7):1206-1208.

Citations and Reference Literature: Coenzyme Q10

- Lamperti C, Naini AB, Lucchini V, et al. Muscle coenzyme Q10 level in statin-related myopathy. *Arch Neurol* 2005;62(11):1709-1712.
- Lampertico M, Comis S. Italian multicenter study on the efficacy and safety of coenzyme Q10 as adjuvant therapy in heart failure. *Clin Investig* 1993;71(8 Suppl):S129-S133.
- Lamson DW, Plaza SM. Mitochondrial factors in the pathogenesis of diabetes: a hypothesis for treatment. *Altern Med Rev* 2002;7(2):94-111.
- Langsjoen PH, Folkers K, Lyson K, et al. Pronounced increase of survival of patients with cardiomyopathy when treated with coenzyme Q10 and conventional therapy. *Int J Tissue React* 1990;12(3):163-168.
- Langsjoen PH, Langsjoen AM. Overview of the use of CoQ10 in cardiovascular disease. *Biofactors* 1999;9(2-4):273-284.
- Langsjoen PH, Langsjoen AM. The clinical use of HMG CoA-reductase inhibitors and the associated depletion of coenzyme Q10: a review of animal and human publications. *Biofactors* 2003;18(1-4):101-111. (Review)
- Langsjoen PH, Langsjoen PH, Folkers K. A six-year clinical study of therapy of cardiomyopathy with coenzyme Q10. *Int J Tissue React* 1990;12(3):169-171.
- Langsjoen PH, Langsjoen PH, Folkers K. Isolated diastolic dysfunction of the myocardium and its response to CoQ 10 treatment. *Clin Investig* 1993;71(8 Suppl):S140-S144.
- Langsjoen PH, Langsjoen PH, Folkers K. Long-term efficacy and safety of coenzyme Q10 therapy for idiopathic dilated cardiomyopathy. *Am J Cardiol* 1990;65(7):521-523.
- Langsjoen H, Langsjoen P, Langsjoen P, et al. Usefulness of coenzyme Q10 in clinical cardiology: a long-term study. *Mol Aspects Med* 1994;15(Suppl):S165-S175.
- Langsjoen P, Langsjoen P, Willis R, et al. Treatment of essential hypertension with coenzyme Q10. *Mol Aspects Med* 1994;15(Suppl):S265-S272.
- Langsjoen PH, Vadhanavikit S, Folkers K. Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10. *Proc Natl Acad Sci U S A* 1985;82(12):4240-4244.
- Larsson O. Effects of isoprenoids on growth of normal human mammary epithelial cells and breast cancer cells in vitro. *Anticancer Res* 1994;14:123-128.
- Lerman-Sagie T, Rustin P, Lev D, et al. Dramatic improvement in mitochondrial cardiomyopathy following treatment with idebenone. *J Inherit Metab Dis* 2001;24(1):28-34.
- Levy HB, Kohlhaas HK. Considerations for supplementing with coenzyme q10 during statin therapy. *Ann Pharmacother* 2006;40(2):290-294.
- Li G, Zou L, Jack CR Jr, et al. Neuroprotective effect of Coenzyme Q10 on ischemic hemisphere in aged mice with mutations in the amyloid precursor protein. *Neurobiol Aging* 2006. Epub ahead of print.
- Linnane AW, Kopsidas G, Zhang C, et al. Cellular redox activity of coenzyme Q10: effect of CoQ10 supplementation on human skeletal muscle. *Free Radic Res* 2002;36(4):445-453.
- Linnane AW, Zhang C, Yarovaya N, et al. Human aging and global function of coenzyme Q10. *Ann N Y Acad Sci* 2002;959:396-411; discussion 463-465. (Review)
- Littarru GP, Tiano L. Clinical aspects of coenzyme Q10: an update. *Curr Opin Clin Nutr Metab Care* 2005;8(6):641-646. (Review)
- Lockwood K, Moesgaard S, Folkers K. Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10. *Biochem Biophys Res Commun* 1994;199(3):1504-1508.
- Lockwood K, Moesgaard S, Hanioka T, et al. Apparent partial remission of breast cancer in 'high risk' patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10. *Mol Aspects Med* 1994;15(Suppl):s231-s240.
- Lockwood K, Moesgaard S, Yamamoto T, et al. Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. *Biochem Biophys Res Commun* 1995;212(1):172-177.
- Lonnrot K, Tolvanen JP, Porsti I, et al. Coenzyme Q10 supplementation and recovery from ischemia in senescent rat myocardium. *Life Sci* 1999;64(5):315-323.
- Loop RA, Anthony M, Willis RA, et al. Effects of ethanol, lovastatin and coenzyme Q10 treatment on antioxidants and TBA reactive material in liver of rats. *Mol Aspects Med* 1994;15(Suppl):s195-s206.
- Lubawy WC, Whaley J, Hurley LH. Coenzyme Q10 or alpha-tocopherol reduce the acute toxicity of anthramycin in mice. *Res Commun Chem Pathol Pharmacol* 1979;24(2):401-404.
- Ludwig FC, Elashoff RM, Smith JL, et al. Response of the bone marrow of the vitamin E-deficient rabbit to coenzyme Q and vitamin E. *Scand J Haematol* 1967;4(4):292-300.
- Lynch JW, Everson SA, Kaplan GA, et al. Does low socioeconomic status potentiate the effects of heightened cardiovascular responses to stress on the progression of carotid atherosclerosis? *Am J Public Health* 1998;88(3):389-394.
- Malm C, Svensson M, Ekblom B, et al. Effects of ubiquinone-10 supplementation and high intensity training on physical performance in humans. *Acta Physiol Scand* 1997;161(3):379-384.

Citations and Reference Literature: Coenzyme Q10

- Manuel DG, Kwong K, Tanuseputro P, et al. Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: modelling study. *BMJ* 2006;332:1419.
- Manzoli U, Rossi E, Littarru GP, et al. Coenzyme Q10 in dilated cardiomyopathy. *Int J Tissue React* 1990;12:173-178.
- Mar R, Pajukanta P, Allayee H, et al. Association of the APOLIPOPROTEIN A1/C3/A4/A5 gene cluster with triglyceride levels and LDL particle size in familial combined hyperlipidemia. *Circ Res* 2004;94(7):993-999.
- Matsumura T, Saji S, Nakamura R, et al. Evidence for enhanced treatment of periodontal disease by therapy with coenzyme Q. *Int J Vitam Nutr Res* 1973;43(4):537-548.
- Matthews RT, Yang L, Browne S, et al. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. *Proc Natl Acad Sci U S A* 1998; 95:8892-8897.
- Mattila P, Kumpulainen J. Coenzymes Q9 and Q10: contents in foods and dietary intake. *J Food Comp Anal* 2001;14(4):409-417.
- Maulik N, Yoshida T, Engelman RM, et al. Dietary coenzyme Q(10) supplement renders swine hearts resistant to ischemia-reperfusion injury. *Am J Physiol Heart Circ Physiol* 2000;278(4):H1084-1090.
- May HT, Muhlestein JB, Carlquist JF, et al. Relation of serum total cholesterol, C-reactive protein levels, and statin therapy to survival in heart failure. *Am J Cardiol* 2006;98(5):653-658. Epub 2006.
- Mazzola C, Guffanti EE, Vaccarella A, et al. Noninvasive assessment of coenzyme Q10 in patients with chronic stable effort angina and moderate heart failure. *Curr Ther Res* 1987;41(6):923-932.
- McGwin G Jr, Modjarrad K, Hall A, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the presence of age-related macular degeneration in the Cardiovascular Health Study. *Arch Ophthalmol* 2006;124:33-37.
- McDonnell MG, Archbold GP. Plasma ubiquinol/cholesterol ratios in patients with hyperlipidaemia, those with diabetes mellitus and in patients requiring dialysis. *Clin Chim Acta* 1996;253(1-2):117-126.
- Meisinger C, Loewel H, Mraz W, et al. Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study. *Eur Heart J* 2005;26(3):271-278.
- Menke T, Gille G, Reber F, et al. Coenzyme Q10 reduces the toxicity of rotenone in neuronal cultures by preserving the mitochondrial membrane potential. *Biofactors* 2003;18(1-4):65-72.
- Menke T, Niklowitz P, Reinehr T, et al. Plasma levels of coenzyme Q10 in children with hyperthyroidism. *Horm Res* 2004;61(4):153-158.
- Miles MV, Horn PS, Morrison JA, et al. Plasma coenzyme Q10 reference intervals, but not redox status, are affected by gender and race in self-reported healthy adults. *Clin Chim Acta* 2003;332(1-2):123-132.
- Mohr D, Bowry VW, Stocker R. Dietary supplementation with coenzyme Q10 results in increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance of human low-density lipoprotein to the initiation of lipid peroxidation. *Biochim Biophys Acta* 1992;1126(3):247-254.
- Morisco C, Trimarco B, Condorelli M. Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. *Clin Investig* 1993;71(8 Suppl):S134-S136.
- Mosca F, Fattorini D, Bompadre S, et al. Assay of coenzyme Q(10) in plasma by a single dilution step. *Anal Biochem* 2002;305(1):49-54.
- Moss RW. Should patients undergoing chemotherapy and radiotherapy be prescribed antioxidants? *Integr Cancer Ther* 2006;5(1):3-6.
- Mortensen SA. Coenzyme Q10 as an adjunctive therapy in patients with congestive heart failure. *J Am Coll Cardiol* 2000;36(1):304-305.
- Mortensen SA. Overview on coenzyme Q10 as adjunctive therapy in chronic heart failure: rationale, design and end-points of "Q-symbio": a multinational trial. *Biofactors* 2003;18(1-4):79-89.
- Mortensen SA. Perspectives on therapy of cardiovascular diseases with coenzyme Q10 (ubiquinone). *Clin Invest* 1993;71:S116-S123. (Review)
- Mortensen SA, Leth A, Agner E, et al. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. *Mol Aspects Med* 1997;18(Suppl):S137-S144.
- Mortensen SA, Vadhanavikit S, Baandrup U, et al. Long-term coenzyme Q10 therapy: a major advance in the management of resistant myocardial failure. *Drug Exp Clin Res* 1985;11:581-593.
- Mortensen SA, Vadhanavikit S, Muratsu K, et al. Coenzyme Q10: clinical benefits with biochemical correlates suggesting a scientific breakthrough in the management of chronic heart failure. *Int J Tissue React* 1990;12(3):155-162.
- Morton RA. Ubiquinones, plastoquinones and vitamins K. *Biol Rev Camb Philos Soc* 1971;46:47-96.
- Muller T, Buttner T, Gholipour AF, et al. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease. *Neurosci Lett* 2003;341(3):201-204.
- Munkholm H, Hansen HH, Rasmussen K. Coenzyme Q10 treatment in serious heart failure. *Biofactors* 1999;9(2-4):285-289.

Citations and Reference Literature: Coenzyme Q10

- Munnich A, Rotig A, Cormier-Daire V, et al. Clinical presentation of respiratory chain deficiency. In: Scriver CR, Beaudet AL, Sly WS, et al, eds. *The metabolic and molecular bases of inherited disease*. Vol 2. 8th ed. New York: McGraw-Hill; 2001:2261-2274.
- Murashige N, Hiroshi I, Matsuo K, et al. Increased incidence of lymphoid malignancies in patients receiving statins (HMG-CoA reductase inhibitors): a case-control study involving 1102 patients. *Blood* 2002;100:467a.
- Musumeci O, Naini A, Slonim AE, et al. Familial cerebellar ataxia with muscle coenzyme Q10 deficiency. *Neurology* 2001;56(7):849-855.
- Nakamura N, Hamazaki T, Ohta M, et al. Joint effects of HMG-CoA reductase inhibitors and eicosapentaenoic acids on serum lipid profile and plasma fatty acid concentrations in patients with hyperlipidemia. *Int J Clin Lab Res* 1999;29:22-25.
- Naini A, Lewis VJ, Hirano M, et al. Primary coenzyme Q10 deficiency and the brain. *Biofactors* 2003;18(1-4):145-152.
- Nicholls SJ, Tuzcu EM, Sipahi I, et al. Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study). *Am J Cardiol* 2006;97(11):1553-1557.
- Niibori K, Yokoyama H, Crestanello JA, et al. Acute administration of liposomal coenzyme Q10 increases myocardial tissue levels and improves tolerance to ischemia reperfusion injury. *J Surg Res* 1998;79:141-145.
- Nielsen AN, Mizuno M, Ratkevicius A, et al. No effect of antioxidant supplementation in triathletes on maximal oxygen uptake, 31P-NMRS detected muscle energy metabolism and muscle fatigue. *Int J Sports Med* 1999;20(3):154-158.
- Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. *JAMA* 2004;291(9):1071-1080.
- Nohl H, Gille L. The role of coenzyme Q in lysosomes. In: Kagan VE, Quinn PJ, eds. *Coenzyme Q: molecular mechanisms in health and disease*. Boca Raton: CRC Press; 2001:99-106.
- Nohl H, Staniek K, Kozlov AV, et al. The biomolecule ubiquinone exerts a variety of biological functions. *Biofactors* 2003;18(1-4):23-31.
- Oda T. Effect of coenzyme Q 10 on stress-induced cardiac dysfunction in paediatric patients with mitral valve prolapse: a study by stress echocardiography. *Drugs Exp Clin Res* 1985;11(8):557-576.
- Ogasahara S, Nishikawa Y, Yorifuji S, et al. Treatment of Kearns-Sayre syndrome with coenzyme Q10. *Neurology* 1986;36(1):45-53.
- Ogura F, Morii H, Ohno M, et al. Serum coenzyme Q10 levels in thyroid disorders. *Horm Metab Res* 1980;12(10):537-540.
- Ogura R, Toyama H, Shimada T, et al. The role of ubiquinone (coenzyme Q10) in preventing Adriamycin®-induced mitochondrial disorders in rat heart. *J Appl Biochem* 1979;1:325.
- Okamoto H, Kawaguchi H, Togashi H, et al. Effect of coenzyme Q 10 on structural alterations in the renal membrane of stroke-prone spontaneously hypertensive rats. *Biochem Med Metab Biol* 1991;45(2):216-226.
- Overvad K, Diamant B, Holm L, et al. Coenzyme Q10 in health and disease. *Eur J Clin Nutr* 1999;53(10):764-770.
- Palazzoni G, Pucello D, Littarru GP, et al. Coenzyme Q10 and colorectal neoplasms in aged patients. *Rays* 1997;22(Suppl 1):73-76.
- Pandolfi C, Ferrari D, Stanic I, et al. [Circulating levels of CoQ10 in hypo- and hyperthyroidism.] *Minerva Endocrinol* 1994;19(3):139-142. [Italian]
- Pedersen TR, Faergeman O, Kastelein JJP, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL Study: a randomized controlled trial. *JAMA* 2005;294:2437-2445.
- Pepping J. Coenzyme Q10. *Am J Health Syst Pharm* 1999;56(6):519-521. (Review)
- Permanetter B, Rossy W, Klein G, et al. Ubiquinone (coenzyme Q10) in the long-term treatment of idiopathic dilated cardiomyopathy. *Eur Heart J* 1992;13(11):1528-1533.
- Piorkowski JD Jr. Bayer's response to "potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis." *JAMA* 2004;292(21):2655-2659.
- Pogessi L, Galanti G, Corneglio M, et al. Effect of coenzyme Q10 on left ventricular function in patients with dilative cardiomyopathy. *Curr Ther Res* 1991;49:878-886.
- Portakal O, Ozkaya O, Erden Inal M, et al. Coenzyme Q 10 concentrations and antioxidant status in tissues of breast cancer patients. *Clin Biochem* 2000;33(4):279-284.
- Porter DA, Costill DL, Zachwieja JJ, et al. The effect of oral coenzyme Q10 on the exercise tolerance of middle-aged, untrained men. *Int J Sports Med* 1995;16(7):421-427.
- Psaty BM, Furberg CD, Ray WA, et al. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. *JAMA* 2004;292(21):2622-2631.
- Raitakari OT, McCredie RJ, Witting P, et al. Coenzyme Q improves LDL resistance to ex vivo oxidation but does not enhance endothelial function in hypercholesterolemic young adults. *Free Radic Biol Med* 2000;28(7):1100-1105.

Citations and Reference Literature: Coenzyme Q10

- Rapoport AM, Bigal ME. Migraine preventive therapy: current and emerging treatment options. *Neurol Sci* 2005;26(Suppl 2):s111-s120. (Review)
- Ravnskov U, Rosch PJ, Sutter MC, et al. Should we lower cholesterol as much as possible? *BMJ* 2006;332(7553):1330-1332. (Letter)
- Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. *N Engl J Med* 2005;352(1):20-28.
- Risser N, Murphy M. The promising future of coenzyme q10. *Nurse Pract* 2005;30(11):66-67.
- Rosenfeldt F, Hilton D, Pepe S, et al. Systematic review of effect of coenzyme Q10 in physical exercise, hypertension and heart failure. *Biofactors* 2003;18(1-4):91-100.
- Rosenfeldt FL, Pepe S, Linnane A, et al. The effects of ageing on the response to cardiac surgery: protective strategies for the ageing myocardium. *Biogerontology* 2002;3(1-2):37-40.
- Rosenfeldt FL, Pepe S, Linnane A, et al. Coenzyme Q10 protects the aging heart against stress: studies in rats, human tissues, and patients. *Ann N Y Acad Sci* 2002;959:355-359; discussion 463-465.
- Rosenhek R. Statins for aortic stenosis. *N Engl J Med* 2005;352:2441-2443. (Editorial)
- Ross R. Atherosclerosis: an inflammatory disease. *N Engl J Med* 1999;340(2):115-126.
- Rotig A, Appelkvist EL, Geromel V, et al. Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency. *Lancet* 2000;356(9227):391-395.
- Rozen TD, Oshinsky ML, Gebeline CA, et al. Open label trial of coenzyme Q10 as a migraine preventive. *Cephalalgia* 2002;22(2):137-141.
- Rusciani L, Proietti I, Rusciani A, et al. Low plasma coenzyme Q10 levels as an independent prognostic factor for melanoma progression. *J Am Acad Dermatol* 2006;54(2):234-241.
- Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. *N Engl J Med* 1996;335:1001-1009.
- Sandor PS, Afra J. Nonpharmacologic treatment of migraine. *Curr Pain Headache Rep* 2005;9(3):202-205.
- Sandor PS, Di Clemente L, Coppola G, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. *Neurology* 2005;64(4):713-715.
- Sarter B. Coenzyme Q10 and cardiovascular disease: a review. *J Cardiovasc Nurs* 2002;16(4):9-20. (Review)
- Satoh K, Yamato A, Nakai T, et al. Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischaemic dog hearts. *Br J Pharmacol* 1995;116:1894-1898.
- Schilling G, Coonfield ML, Ross CA, et al. Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. *Neurosci Lett* 2001;315(3):149-153.
- Schmermund A, Achenbach S, Budde T, et al. Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months. a multicenter, randomized, double-blind trial. *Circulation* 2006;113:427-437.
- Shults CW, Beal MF, Fontaine D, et al. Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients. *Neurology* 1998;50(3):793-795.
- Scott GN, Elmer GW. Update on natural product-drug interactions. *Am J Health-Syst Pharm* 2002;59(4):339-347.
- Sharma SK, Ebadi M. Metallothionein attenuates 3-morpholinostyrylamine (SIN-1)-induced oxidative stress in dopaminergic neurons. *Antioxid Redox Signal* 2003;5(3):251-264.
- Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial: PRO-spective Study of Pravastatin in the Elderly at Risk. *Lancet* 2002;360:1623-1630.
- Shigeta Y, Izumi K, Abe H. Effect of coenzyme Q7 treatment on blood sugar and ketone bodies of diabetics. *J Vitaminol* 1966;12:293-298.
- Shils ME, Olson JA, Shike M, et al. Modern nutrition in health and disease. 9th ed. Baltimore: Williams & Wilkins; 1999:90-92, 1377-1378.
- Shoffner JM. Oxidative phosphorylation diseases. In: Scriver CR, Beaudet AL, Sly WS, et al, eds. The metabolic and molecular bases of inherited disease. Vol 2. 8th ed. New York: McGraw-Hill; 2001:2367-2392.
- Shults CW, Beal MF, Fontaine D, et al. Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients. *Neurology* 1998;50(3):793-795.
- Shults CW, Haas RH, Beal MF. A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease. *Biofactors* 1999;9(2-4):267-272.
- Shults CW, Haas RH, Passov D, et al. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. *Ann Neurol* 1997;42(2):261-264.

Citations and Reference Literature: Coenzyme Q10

- Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. *Arch Neurol* 2002;59(10):1541-1550.
- Sikorska M, Borowy-Borowski H, Zurakowski B, et al. Derivatized alpha-tocopherol as a CoQ10 carrier in a novel water-soluble formulation. *Biofactors* 2003;18(1-4):173-183.
- Silver MA, Langsjoen PH, Szabo S, et al. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q(10) to reverse that dysfunction. *Am J Cardiol* 2004;94(10):1306-1310.
- Silver MA, Langsjoen PH, Szabo S, et al. A. Statin cardiomyopathy? A potential role for co-enzyme Q10 therapy for statin-induced changes in diastolic LV performance: description of a clinical protocol. *Biofactors* 2003;18(1-4):125-127.
- Simkovic M, Freman FE. Alternative quinone substrates and inhibitors of human electron-transfer flavoprotein-ubiquinone oxidoreductase. *Biochem J* 2004;378(Pt 2):633-640.
- Sinatra DS, Sinatra ST, Heyser CJ. The effects of coenzyme Q10 on locomotor and behavioral activity in young and aged C57BL/6 mice. *Biofactors* 2003;18(1-4):283-287.
- Sinatra ST. Alternative medicine for the conventional cardiologist. *Heart Dis* 2000;2(1):16-30. (Review)
- Sinatra ST. "Care," cancer and coenzyme Q10. *J Am Coll Cardiol* 1999;33(3):897-899. (Letter; Comment)
- Sinatra ST. Coenzyme Q10 and congestive heart failure. *Ann Intern Med* 2000;133(9):745-746. (Letter)
- Sinatra ST. Coenzyme Q10: a vital therapeutic nutrient for the heart with special application in congestive heart failure. *Conn Med* 1997;61(11):707-711.
- Sinatra ST. Is cholesterol lowering with statins the gold standard for treating patients with cardiovascular risk and disease? *South Med J* 2003;96(3):220-222. (Editorial)
- Sinatra ST. Refractory congestive heart failure successfully managed with high dose coenzyme Q10 administration. *Mol Aspects Med* 1997;18(Suppl):S299-S305.
- Sinatra ST, DeMarco J. Free radicals, oxidative stress, oxidized low density lipoprotein (LDL), and the heart: antioxidants and other strategies to limit cardiovascular damage. *Conn Med* 1995;59(10):579-588. (Review)
- Singh RB, Khanna HK, Niaz MA. Randomized, double-blind placebo-controlled trial of coenzyme Q10 in chronic renal failure: discovery of a new role. *J Nutr Environ Med* 2000;10:281-288.
- Singh RB, Kumar A, Niaz MA, et al. Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in patients with end-stage renal failure. *J Nutr Environ Med* 2003;13(1):13-22.
- Singh RB, Niaz MA, Rastogi SS, et al. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. *J Hum Hypertens* 1999;13(3):203-208.
- Singh RB, Singh MM. Effect of coenzyme Q10 in new indications with antioxidant vitamin deficiency. *J Nutr Environ Med* 1999;9:223-228.
- Singh RB, Wander GS, Rastogi A, et al. Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction. *Cardiovasc Drugs Ther* 1998;12(4):347-353.
- Siri PW, Krauss RM. Influence of dietary carbohydrate and fat on LDL and HDL particle distributions. *Curr Atheroscler Rep* 2005;7(6):455-459.
- Sirtori CR, Calabresi L. Japan: are statins still good for everybody? *Lancet* 2006;368(9542):1135-1136.
- Sobreira C, Hirano M, Shanske S, et al. Mitochondrial encephalomyopathy with coenzyme Q10 deficiency. *Neurology* 1997;48(5):1238-1243.
- Soderberg M, Edlund C, Kristensson K, et al. Lipid compositions of different regions of the human brain during aging. *J Neurochem* 1990;54(2):415-423.
- Soja AM, Mortensen SA. [Treatment of chronic cardiac insufficiency with coenzyme Q10, results of meta-analysis in controlled clinical trials.] *Ugeskr Laeger* 1997;159(49):7302-7308.
- Stange KC, Acheson LS. Communication in the era of 'personalized' medicine. *Ann Fam Med* 2006;4(3):194-196. (Editorial)
- Stricker RB, Goldberg B. Is cholesterol lowering with statins the gold standard for treating patients with cardiovascular risk and disease? *South Med J* 2003;96(8):837-838. (Letter)
- Strom BL. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: a counterpoint. *JAMA* 2004;292(21):2643-2646.
- Sunamori M, Tanaka H, Maruyama T, et al. Clinical experience of coenzyme Q10 to enhance intraoperative myocardial protection in coronary artery revascularization. *Cardiovasc Drugs Ther* 1991;5(Suppl 2):297-300.
- Suzuki S, Hinokio Y, Ohtomo M, et al. The effects of coenzyme Q10 treatment on maternally inherited diabetes mellitus and deafness, and mitochondrial DNA 3243 (A to G) mutation. *Diabetologia* 1998;41(5):584-588.

Citations and Reference Literature: Coenzyme Q10

- Svensson M, Malm C, Tonkonogi M, et al. Effect of Q10 supplementation on tissue Q10 levels and adenine nucleotide catabolism during high-intensity exercise. *Int J Sport Nutr* 1999;9(2):166-180.
- Taggart DP, Jenkins M, Hooper J, et al. Effects of short-term supplementation with coenzyme Q10 on myocardial protection during cardiac operations. *Ann Thorac Surg* 1996;61(3):829-833.
- Tanaka J, Tominaga R, Yoshitoshi M, et al. Coenzyme Q10: the prophylactic effect on low cardiac output following cardiac valve replacement. *Ann Thorac Surg* 1982;33(2):145-151.
- Tarnopolsky MA, Raha S. Mitochondrial myopathies: diagnosis, exercise intolerance, and treatment options. *Med Sci Sports Exerc* 2005;37(12):2086-2093.
- Thavendiranathan P, Bagaï A, Brookhart MA, et al. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. *Arch Intern Med* 2006;166:2307-2313.
- Thomas SR, Leichtweis SB, Pettersson K, et al. Dietary cosupplementation with vitamin E and coenzyme Q(10) inhibits atherosclerosis in apolipoprotein E gene knockout mice. *Arterioscler Thromb Vasc Biol* 2001;21(4):585-593.
- Thomas SR, Neuzil J, Stocker R. Inhibition of LDL oxidation by ubiquinol-10: a protective mechanism for coenzyme Q in atherogenesis? *Mol Aspects Med* 1997;18:S85-S103.
- Thomas SR, Stocker R. Mechanisms of antioxidant action of ubiquinol-10 for low-density lipoprotein. In: Kagan VE, Quinn PJ, eds. *Coenzyme Q: molecular mechanisms in health and disease*. Boca Raton, FL: CRC Press; 2001:131-150.
- Thorsteindottir B, Rafnsdottir S, Geirsson AJ, et al. No difference in ubiquinone concentration of muscles and blood in fibromyalgia patients and healthy controls. *Clin Exp Rheumatol* 1998;16:513-514.
- Topol EJ. Intensive statin therapy: a sea change in cardiovascular prevention. *N Engl J Med* 2004;350(15):1562-1564. (Editorial)
- Tran MT, Mitchell TM, Kennedy DT, et al. Role of coenzyme Q10 in chronic heart failure, angina, and hypertension. *Pharmacotherapy* 2001;21(7):797-806.
- Trupp RJ, Abraham WT. Congestive heart failure. In: Rakel RE, Bope ET, eds. *Rakel: Conn's current therapy* 2002. 54th ed. New York: Saunders Company; 2002:306-313.
- Tsivgoulis G, Spengos K, Karandreas N, et al. Presymptomatic neuromuscular disorders disclosed following statin treatment. *Arch Intern Med* 2006;166:1519-1524.
- Turunen M, Wehlin L, Sjöberg M, et al. beta2-Integrin and lipid modifications indicate a non-antioxidant mechanism for the anti-atherogenic effect of dietary coenzyme Q10. *Biochem Biophys Res Commun* 2002;296(2):255-260.
- van der Steeg WA, Kuivenhoven JA, Klerkx AH, et al. Role of CETP inhibitors in the treatment of dyslipidemia. *Curr Opin Lipidol* 2004;15(6):631-636. (Review)
- van Gaal L, Folkers K, Yamamura Y, eds. Exploratory study of coenzyme Q 10. In: *Obesity, biomedical and clinical aspects of coenzyme Q*. Vol 4. Amsterdam: Elsevier Science Publications; 1984:369-373.
- Virmani A, Gaetani F, Binienda Z. Effects of metabolic modifiers such as carnitines, coenzyme Q10, and PUFAs against different forms of neurotoxic insults: metabolic inhibitors, MPTP, and methamphetamine. *Ann N Y Acad Sci* 2005;1053:183-191.
- Walldius G, Jungner I. Rationale for using apolipoprotein B and apolipoprotein A-I as indicators of cardiac risk and as targets for lipid-lowering therapy. *Eur Heart J* 2005;26(3):210-212. (Editorial)
- Wang D, Taylor, KD, Smith J, et al. IL1B and TRAF6 are associated with components of low-density lipoprotein cholesterol reduction during statin therapy. Poster 3. American Heart Association Scientific Sessions 2005. Dallas, Nov 14, 2005.
- Wang QF, Liu X, O'Connell J, et al. Haplotypes in the APOA1-C3-A4-A5 gene cluster affect plasma lipids in both humans and baboons. *Hum Mol Genet* 2004;13(10):1049-1056.
- Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. *N Engl J Med* 2006;355(25):2631-2639.
- Ware JH. The limitations of risk factors as diagnostic tools. *N Engl J Med* 2006;355(25):2615-2617. (Editorial)
- Watson PS, Scalia GM, Galbraith A, et al. Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure. *J Am Coll Cardiol* 1999;33:1549-1552.
- Watts GF, Cummings MH, Umpleby M, et al. Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications. *Eur J Clin Invest* 1995;25:559-567.
- Watts GF, Playford DA, Croft KD, et al. Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in type II diabetes mellitus. *Diabetologia* 2002;45(3):420-426.
- Watts TL. Coenzyme Q10 and periodontal treatment: is there any beneficial effect? *Br Dent J* 1995;178(6):209-213.
- Weber C. Dietary intake and absorption of coenzyme Q. In: Kagan VE, Quinn PJ, eds. *Coenzyme Q: molecular mechanisms in health and disease*. Boca Raton, FL: CRC Press; 2001:209-215.

Citations and Reference Literature: Coenzyme Q10

- Weber C, Jakobsen TS, Mortensen SA, et al. Antioxidative effect of dietary coenzyme Q10 in human blood plasma. *Int J Vitam Nutr Res* 1994;64:311-315.
- Wei L, Murphy MJ, MacDonald TM. Impact on cardiovascular events of increasing high density lipoprotein cholesterol with and without lipid lowering drugs. *Heart* 2006;92(6):746-751.
- Weiss M. Bioavailability of four oral coenzyme Q10 formulations in healthy volunteers. *Mol Aspects Med* 1994;15(Suppl):S273-S280.
- Werbach MR. Foundations of nutritional medicine. Tarzana, CA: Third Line Press; 1997. (Review)
- Werbach MR. Nutritional influences on illness. 2nd ed. Tarzana, CA: Third Line Press; 1993:66, 119, 122, 179, 421. (Review)
- Werbach MR. Nutritional strategies for treating chronic fatigue syndrome. *Altern Med Rev* 2000;5(2):93-108.
- Weston SB, Zhou S, Weatherby RP, et al. Does exogenous coenzyme Q10 affect aerobic capacity in endurance athletes? *Int J Sport Nutr* 1997;7(3):197-206.
- Wilke RA, Moore JH, Burmester JK. Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. *Pharmacogenet Genomics* 2005;15(6):415-421.
- Wilkinson EG, Arnold RM, Folkers K, et al. Bioenergetics in clinical medicine: II: adjunctive treatment with coenzyme Q in periodontal therapy. *Res Commun Chem Pathol Pharmacol* 1975;12(1):111-123.
- Wilkinson EG, Arnold RM, Folkers K. Bioenergetics in clinical medicine: VI: adjunctive treatment of periodontal disease with coenzyme Q10. *Res Commun Chem Pathol Pharmacol* 1976;14(4):715-719.
- Willis R, Anthony M, Sun L, et al. Clinical implications of the correlation between coenzyme Q10 and vitamin B6 status. *Biofactors* 1999;9(2-4):359-363.
- Willis RA, Folkers K, Tucker JL, et al. Lovastatin decreases coenzyme Q levels in rats. *Proc Natl Acad Sci U S A* 1990;87(22):8928-8930.
- Witte KKA, Nikitin NP, Parker AC, et al. The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. *Eur Heart J* 2005;26:2238-2244.
- Witting PK, Pettersson K, Letters J, et al. Anti-atherogenic effect of coenzyme Q10 in apolipoprotein E gene knockout mice. *Free Radic Biol Med* 2000;29(3-4):295-305.
- Wold LE, Muralikrishnan D, Albano CB, et al. Insulin-like growth factor I (IGF-1) supplementation prevents diabetes-induced alterations in coenzymes Q9 and Q10. *Acta Diabetol* 2003;40(2):85-90.
- Yamagami T, Iwamoto Y, Folkers K. Deficiency of activity of succinate dehydrogenase-coenzyme Q10 reductase in leucocytes from patients with essential hypertension. *Int J Vitam Nutr Res* 1974;44(3):404-414.
- Yamagami T, Shibata N, Folkers K. Bioenergetics in clinical medicine: VIII: administration of coenzyme Q10 to patients with essential hypertension. *Res Commun Chem Pathol Pharmacol* 1976;14(4):721-727.
- Yamagami T, Shibata N, Folkers K. Bioenergetics in clinical medicine: studies on coenzyme Q10 and essential hypertension. *Res Commun Chem Pathol Pharmacol* 1975;11(2):273-288.
- Yamagami T, Takagi M, Akagami H, et al. Effect of coenzyme Q10 on essential hypertension: a double-blind controlled study. In: Folkers K, Yamamura Y, eds. *Biomedical and clinical aspects on coenzyme Q*. Amsterdam: Elsevier; 1986:337-343.
- Yan J, Fujii K, Yao J, et al. Reduced coenzyme Q10 supplementation decelerates senescence in SAMP1 mice. *Exp Gerontol* 2006;41(2):130-140.
- Yeshurun D, Slobodin G, Keren D, et al. Statin escape phenomenon: does it really exist? *Eur J Intern Med* 2005;16(3):192-194.
- Yikoski T, Piirainen J, Hanninen O, et al. The effect of coenzyme Q10 on the exercise performance of cross-country skiers. *Mol Aspects Med* 1997;18(Suppl):s283-s290.
- Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid (EPA) on major cardiovascular events in hypercholesterolemic patients: the Japan EPA Lipid Intervention Study (JELIS). *American Heart Association Scientific Sessions* 2005. Dallas, Nov 14, 2005.
- Young AJ, Johnson S, Steffens DC, et al. Coenzyme Q10: a review of its promise as a neuroprotectant. *CNS Spectr* 2007;12(1):62-68. (Review)
- Zhou Q, Chan E. Accuracy of repeated blood sampling in rats: a new technique applied in pharmacokinetic/pharmacodynamic studies of the interaction between warfarin and co-enzyme Q10. *J Pharmacol Toxicol Methods* 1998;40(4):191-199.
- Zhou S, Chan E. Effect of ubiquinol on warfarin anticoagulation and pharmacokinetics of warfarin enantiomers in rats. *Drug Metabol Drug Interact* 2001;18(2):99-122.
- Zhou M, Zhi Q, Tang Y, et al. Effects of coenzyme Q10 on myocardial protection during cardiac valve replacement and scavenging free radical activity in vitro. *J Cardiovasc Surg (Torino)* 1999;40(3):355-361.
- Zita C, Overvad K, Mortensen SA, et al. Serum coenzyme Q10 concentrations in healthy men supplemented with 30 mg or 100 mg coenzyme Q10 for two months in a randomised controlled study. *Biofactors* 2003;18(1-4):185-193.

Citations and Reference Literature: Coenzyme Q10